| Abstrakt: |
A recent study conducted by researchers at Anhui Medical University in Hefei, China, explored the potential of a Chinese medicine monomer called aurantiamide (AA) as a therapeutic drug for acute kidney injury (AKI). The study found that AA demonstrated efficacy in attenuating injury, necroptosis, and inflammatory responses in human renal tubular epithelial cells, as well as ameliorating renal tubular injury and inflammation in mouse models of AKI. The researchers identified the gastrin-releasing peptide receptor (GRPR) as a direct target of AA, and concluded that AA shows promise as a novel antagonist of GRPR and a potential clinical candidate for AKI treatment. [Extracted from the article] |
